Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Innovation Council · Running

IVI-Boost IntraVenous Immune Boost

Coordinator
Hephaistos-Pharma, France
Runs
1 May 2024 to 31 January 2027
Status
Running
EU funding
€2.5m
Total cost
€6.9m
Partners
2 organisations in 2 countries
Type
European Innovation Council
Grant agreement
101145244

What the project is doing

In the project's own words, from its summary on CORDIS.

What if we could finally treat metastatic patients and uncurable cancers like sarcomas ?HEPHAISTOS-Pharma developed ONCO-Boost, the first-in-class intravenous TLR4 immunostimulant that will be a game changer in immunotherapy. This innovation was discovered after 40 years of research from a woman entrepreneur who developed a mature, scalable, disruptive and eco-friendly platform. ONCO-Boost can cure hard to treat cancers as a stand-alone treatment but can also increase the efficacy of existing treatments.

Our cure is injected intravenously and this changes everything, we can offer therapeutic options for patients with metastatic cancers and hardly accessible tumors. As such, ONCO-Boost can cure 10x more patients than competitors, all limited to intratumoral injection. HEPHAISTOS' ambition is to become the European leader in immunostimulants, with a platform able to supply the market with large quantities of drugs, able to save millions of patients each year.

Topics

Who is involved

OrganisationCityCountryRole
Hephaistos-PharmaOrsayFranceCoordinator
Hephaistos-BelgiumLiegeBelgiumThird party

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI